Seoul: SK Biopharmaceuticals Co. said Thursday its 2024 net income reached 227 billion won (US$157 million), turning from a loss of 35.4 billion won a year earlier. Operating profit for the year was 96.3 billion won, compared with a loss of 37.5 billion won from the previous year, the company said in a regulatory filing. Annual sales rose 54.3 percent to 547.6 billion won.

According to Yonhap News Agency, the significant turnaround in SK Biopharmaceuticals' financial performance marks a notable shift from its previous year's losses. The company's impressive increase in sales has been a driving factor in achieving profitability. The regulatory filing highlighted the substantial growth in sales, indicating the company's successful strategies and market presence.